{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:50Z","timestamp":1792460150048,"version":"4.5.0"},"reference-count":144,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Pompe disease, also known as glycogen storage disease type II, is caused by the lack or deficiency of a single enzyme, lysosomal acid alpha-glucosidase, leading to severe cardiac and skeletal muscle myopathy due to progressive accumulation of glycogen. The discovery that acid alpha-glucosidase resides in the lysosome gave rise to the concept of lysosomal storage diseases, and Pompe disease became the first among many monogenic diseases caused by loss of lysosomal enzyme activities. The only disease-specific treatment available for Pompe disease patients is enzyme replacement therapy (ERT) which aims to halt the natural course of the illness. Both the success and limitations of ERT provided novel insights in the pathophysiology of the disease and motivated the scientific community to develop the next generation of therapies that have already progressed to the clinic.<\/jats:p>","DOI":"10.3390\/biom10091339","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T07:06:09Z","timestamp":1600499169000},"page":"1339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Pompe Disease: New Developments in an Old Lysosomal Storage Disorder"],"prefix":"10.3390","volume":"10","author":[{"given":"Naresh K.","family":"Meena","sequence":"first","affiliation":[{"name":"Cell and Developmental Biology Center, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Raben","sequence":"additional","affiliation":[{"name":"Cell and Developmental Biology Center, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cell.2020.01.017","article-title":"SnapShot: Lysosomal Storage Diseases","volume":"180","author":"Martina","year":"2020","journal-title":"Cell"},{"key":"ref_2","first-page":"304","article-title":"Over idiopatische hypertrophie van het hart","volume":"76","author":"Pompe","year":"1932","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalize glycogen storage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1542\/peds.2016-0280C","article-title":"Newborn Screening for Pompe Disease","volume":"140","author":"Bodamer","year":"2017","journal-title":"Pediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tang, H., Feuchtbaum, L., Sciortino, S., Matteson, J., Mathur, D., Bishop, T., and Olney, R.S. (2020). The First Year Experience of Newborn Screening for Pompe Disease in California. Int. J. Neonatal Screen, 6.","DOI":"10.3390\/ijns6010009"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early Detection of Pompe Disease by Newborn Screening Is Feasible: Results From the Taiwan Screening Program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J. Boil. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal Acid \u03b1-Glucosidase Consists of Four Different Peptides Processed from a Single Chain Precursor","volume":"280","author":"Moreland","year":"2004","journal-title":"J. Boil. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dahms, N.M., Lobel, P., and Kornfeld, S. (1989). Mannose 6-phosphate receptors and lysosomal enzyme targeting. J. Boil. Chem., 264.","DOI":"10.1016\/S0021-9258(18)63825-6"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: New twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat. Rev. Mol. Cell Boil."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid \u03b1-glucosidase\u2013a guide for the treatment of Pompe disease","volume":"8","author":"Iacono","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_13","unstructured":"Hirschhorn, R., and Reuser, A.J. (2001). Glycogen Storage Disease Type II: Acid Alphaglucosidase (Acid Maltase) Deficiency. The Metabolic and Molecular Basis of Inherited Disease, McGraw-Hill."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161","author":"Reuser","year":"2013","journal-title":"Am. J. Med Genet. Part A"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: A comprehensive overview","volume":"7","author":"Peruzzo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_16","first-page":"1","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): Molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation","volume":"3","author":"Huie","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"ref_17","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","article-title":"A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II)","volume":"5","author":"Raben","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: Identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2019.03.048","article-title":"A genetic modifier of symptom onset in Pompe disease","volume":"43","author":"Bergsma","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.omtm.2019.12.016","article-title":"Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis","volume":"17","author":"Iuliano","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid \u03b1-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"Lee","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/8904_2015_426","article-title":"Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease","volume":"23","author":"Pena","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: A cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe Disease: Early Diagnosis and Early Treatment Make a Difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ajmg.a.61481","article-title":"Airway abnormalities in very early treated infantile-onset Pompe disease: A large-scale survey by flexible bronchoscopy","volume":"182","author":"Yang","year":"2020","journal-title":"Am. J. Med Genet. Part A"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ymgme.2013.03.016","article-title":"Enzyme replacement therapy and fatigue in adults with Pompe disease","volume":"109","author":"Brusse","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ymgme.2013.05.021","article-title":"Pain in adult patients with Pompe disease","volume":"109","author":"Schober","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"L873","DOI":"10.1152\/ajplung.00568.2016","article-title":"Airway smooth muscle dysfunction in Pompe (GAA-\/-) mice","volume":"312","author":"Keeler","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: A systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): An update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.21037\/atm.2019.06.48","article-title":"Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease","volume":"7","author":"Wencel","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: Results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: A systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2016","journal-title":"J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1540\/jsmr.54.100","article-title":"The impact of Pompe disease on smooth muscle: A review","volume":"54","author":"McCall","year":"2018","journal-title":"J. Smooth Muscle Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","article-title":"Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years","volume":"117","author":"Stepien","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/nan.12580","article-title":"An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease","volume":"46","author":"Kulessa","year":"2019","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_49","first-page":"768-e31","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: A 10-year experience","volume":"24","author":"Kruijshaar","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nmd.2019.11.007","article-title":"Discontinuation of enzyme replacement therapy in adults with Pompe disease: Evaluating the European POmpe Consortium stop criteria","volume":"30","author":"Harlaar","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41436-018-0103-8","article-title":"microRNAs as biomarkers in Pompe disease","volume":"21","author":"Tarallo","year":"2018","journal-title":"Genet. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/acn3.50800","article-title":"Identification of serum microRNAs as potential biomarkers in Pompe disease","volume":"6","author":"Belmonte","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Taverna, S., Cammarata, G., Colomba, P., Sciarrino, S., Zizzo, C., Francofonte, D., Zora, M., Scalia, S., Brando, C., and Curto, A.L. (2020). Pompe disease: Pathogenesis, molecular genetics and diagnosis. Aging, 12.","DOI":"10.18632\/aging.103794"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted Disruption of the Acid \u03b1-Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Boil. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1091\/mbc.e03-09-0704","article-title":"In Vivo Analysis of Autophagy in Response to Nutrient Starvation Using Transgenic Mice Expressing a Fluorescent Autophagosome Marker","volume":"15","author":"Mizushima","year":"2004","journal-title":"Mol. Boil. Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"31582","DOI":"10.1074\/jbc.M506736200","article-title":"Autophagy Is Required for Maintenance of Amino Acid Levels and Protein Synthesis under Nitrogen Starvation","volume":"280","author":"Onodera","year":"2005","journal-title":"J. Boil. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1242\/jeb.124495","article-title":"Muscle memory and a new cellular model for muscle atrophy and hypertrophy","volume":"219","author":"Gundersen","year":"2016","journal-title":"J. Exp. Boil."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cmet.2009.10.008","article-title":"Autophagy Is Required to Maintain Muscle Mass","volume":"10","author":"Masiero","year":"2009","journal-title":"Cell Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4161\/auto.6.2.11137","article-title":"Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles","volume":"6","author":"Masiero","year":"2010","journal-title":"Autophagy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.spen.2006.06.004","article-title":"Autophagic Vacuolar Myopathy","volume":"13","author":"Nishino","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1152\/japplphysiol.01253.2009","article-title":"Impaired organization and function of myofilaments in single muscle fibers from a mouse model of Pompe disease","volume":"108","author":"Xu","year":"2010","journal-title":"J. Appl. Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1038\/cddis.2016.475","article-title":"Autophagy dysregulation in Danon disease","volume":"8","author":"Nascimbeni","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.omtm.2020.05.026","article-title":"Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease","volume":"18","author":"Meena","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ana.20807","article-title":"Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease","volume":"59","author":"Fukuda","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nan.12214","article-title":"Impaired autophagy affects acid \u03b1-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II","volume":"41","author":"Nascimbeni","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_70","first-page":"S42","article-title":"Autophagy in skeletal muscle: Implications for Pompe disease","volume":"47","author":"Shea","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe Disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev-pharmtox-010611-134537","article-title":"AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets","volume":"52","author":"Inoki","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2010.02.024","article-title":"Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids","volume":"141","author":"Sancak","year":"2010","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.1207056","article-title":"mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase","volume":"334","author":"Zoncu","year":"2011","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.tcb.2014.03.003","article-title":"Regulation of mTORC1 by amino acids","volume":"24","author":"Sabatini","year":"2014","journal-title":"Trends Cell Boil."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10662","DOI":"10.1038\/ncomms10662","article-title":"Lysosomal recruitment of TSC2 is a universal response to cellular stress","volume":"7","author":"Demetriades","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2013.11.049","article-title":"Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome","volume":"156","author":"Menon","year":"2014","journal-title":"Cell"},{"key":"ref_79","first-page":"E780","article-title":"Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1","volume":"290","author":"Sakamoto","year":"2005","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4161\/auto.7.6.15123","article-title":"The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR","volume":"7","author":"Egan","year":"2011","journal-title":"Autophagy"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2044-5040-3-6","article-title":"Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy","volume":"3","author":"Bentzinger","year":"2013","journal-title":"Skelet. Muscle"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.2247","article-title":"Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration","volume":"16","author":"Grumati","year":"2010","journal-title":"Nat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1242\/jcs.114041","article-title":"Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies","volume":"126","author":"Sandri","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.15252\/emmm.201606547","article-title":"Modulation of mTOR signaling as a strategy for the treatment of Pompe disease","volume":"9","author":"Lim","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2018.04.025","article-title":"Therapeutic Benefit of Autophagy Modulation in Pompe Disease","volume":"26","author":"Lim","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Shemesh, A., Wang, Y., Yang, Y., Yang, G.S., Johnson, D.E., Backer, J.M., Pessin, J.E., and Zong, H. (2014). Suppression of mTOR1 Activation in Acid- alpha -Glucosidase Deficient Cells and Mice is Ameliorated by Leucine Supplementation. Am. J. Physiol. Regul. Integr. Comp. Physiol.","DOI":"10.1152\/ajpregu.00212.2014"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13473","DOI":"10.1038\/s41598-017-14063-y","article-title":"A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells","volume":"7","author":"Yoshida","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Yoon, M.-S. (2017). mTOR as a Key Regulator in Maintaining Skeletal Muscle Mass. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00788"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/hmg\/dds524","article-title":"mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy","volume":"22","author":"Ching","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Hintze, S., Limmer, S., Dabrowska-Schlepp, P., Berg, B., Krieghoff, N., Busch, A., Schaaf, A., Meinke, P., and Schoser, B. (2020). Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072642"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"125358","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"292","DOI":"10.21037\/atm.2019.05.29","article-title":"Pompe disease: What are we missing?","volume":"7","author":"Schoser","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1152\/physrev.00043.2011","article-title":"Satellite Cells and the Muscle Stem Cell Niche","volume":"93","author":"Yin","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1242\/dev.067595","article-title":"An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration","volume":"138","author":"Lepper","year":"2011","journal-title":"Development"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1101\/sqb.2008.73.064","article-title":"The Molecular Regulation of Muscle Stem Cell Function","volume":"73","author":"Rudnicki","year":"2008","journal-title":"Cold Spring Harb. Symp. Quant. Boil."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-015-0243-x","article-title":"Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease","volume":"3","author":"Schaaf","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40478-018-0620-3","article-title":"Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease","volume":"6","author":"Schaaf","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40478-018-0609-y","article-title":"Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II)","volume":"6","author":"Lagalice","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.15252\/embj.201488278","article-title":"Induction of autophagy supports the bioenergetic demands of quiescent muscle stem cell activation","volume":"33","author":"Tang","year":"2014","journal-title":"EMBO J."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Lim, J.-A., Li, L., and Raben, N. (2014). Pompe disease: From pathophysiology to therapy and back again. Front. Aging Neurosci., 6.","DOI":"10.3389\/fnagi.2014.00177"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe Disease: From Basic Science to Therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: An industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_105","unstructured":"Wenk, J., Hille, A., and Von Figura, K. (1991). Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem. Int., 23."},{"key":"ref_106","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid \u03b1-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered Acid \u03b1-Glucosidase with Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Khanna, R., Flanagan, J.J., Feng, J., Soska, R., Frascella, M., Pellegrino, L.J., Lun, Y., Guillen, D., Lockhart, D.J., and Valenzano, K.J. (2012). The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid \u03b1-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040776"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A Chaperone Enhances Blood \u03b1-Glucosidase Activity in Pompe Disease Patients Treated with Enzyme Replacement Therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"20790","DOI":"10.1074\/jbc.C700090200","article-title":"Intranuclear Protein Transduction through a Nucleoside Salvage Pathway","volume":"282","author":"Hansen","year":"2007","journal-title":"J. Boil. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1535-7163.MCT-12-0476-T","article-title":"A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets","volume":"11","author":"Weisbart","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1038\/srep12022","article-title":"DNA-dependent targeting of cell nuclei by a lupus autoantibody","volume":"5","author":"Weisbart","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ymgme.2018.12.211","article-title":"Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease","volume":"126","author":"Kishnani","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"Beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I\/II Clinical Trial of Clenbuterol in Pompe Disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"15053","DOI":"10.1038\/mtm.2015.53","article-title":"Targeted approaches to induce immune tolerance for Pompe disease therapy","volume":"3","author":"Doerfler","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/atm.2019.04.67","article-title":"Progress and challenges of gene therapy for Pompe disease","volume":"7","author":"Ronzitti","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: Neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated Gene Therapy for Pompe Disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological Correction of Pompe Disease by Systemic Delivery of Adeno-associated Virus Serotype 1 Vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated Delivery of AAV1 Vectors Corrects Ventilatory Function in Pompe Mice with Established Disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained Correction of Motoneuron Histopathology Following Intramuscular Delivery of AAV in Pompe Mice","volume":"22","author":"Elmallah","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II Trial of Adeno-Associated Virus\u2013Mediated Alpha-Glucosidase Gene Therapy to the Diaphragm for Chronic Respiratory Failure in Pompe Disease: Initial Safety and Ventilatory Outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-\u03b1-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymthe.2005.08.006","article-title":"Fully Deleted Adenovirus Persistently Expressing GAA Accomplishes Long-Term Skeletal Muscle Glycogen Correction in Tolerant and Nontolerant GSD-II Mice","volume":"13","author":"Kiang","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/gt.2016.53","article-title":"Long-term, high-level hepatic secretion of acid \u03b1-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus","volume":"23","author":"Rastall","year":"2016","journal-title":"Gene Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of Immune Responses to Introduced Human Acid \u03b1-Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced Response to Enzyme Replacement Therapy in Pompe Disease after the Induction of Immune Tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe Disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"103737","DOI":"10.1016\/j.cellimm.2017.12.011","article-title":"Immunomodulatory, liver depot gene therapy for Pompe disease","volume":"342","author":"Bond","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm.2019.05.02","article-title":"Liver depot gene therapy for Pompe disease","volume":"7","author":"Kishnani","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Cagin, U., Puzzo, F., Gomez, M.J., Moya-Nilges, M., Sellier, P., Abad, C., Van Wittenberghe, L., Daniele, N., Guerchet, N., and Gjata, B. (2020). Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid \u03b1-Glucosidase. Mol. Ther., 28.","DOI":"10.1016\/j.ymthe.2020.05.025"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/9\/1339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:11:30Z","timestamp":1760177490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/9\/1339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":144,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["biom10091339"],"URL":"https:\/\/doi.org\/10.3390\/biom10091339","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}